Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — Q2 2022 Earnings Presentation
14 slides from Adaptive Biotechnologies's earnings presentation, 2022
Slide 1: Second Quarter 2022 Earnings Conference Call
Second Quarter 2022 Earnings Conference Call
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: Q2 2022 Key Highlights
Q2 2022 Key Highlights MRD Business ◼ Significant clonoSEQ test volume growth of 53% vs prior year ◼ Received Medicare coverage for clonoSEQ DLBCL ◼ Signed new pan-portfolio agreement with pharma partner Q2’ 22 Rev Immune Medicine Business $43.7M ◼ Pharma partnerships across diseases increasing (123
Slide 4: MRD Business: clonoSEQ clinical testing
MRD Business: clonoSEQ clinical testing ◼ Q2’22 test delivered volume +53% vs P/Y; +17% vs P/Q ❑ 357 ordering accounts in Q2 (+44% vs P/Y) ❑ 1,445 ordering HCPs in Q2 (+53% vs P/Y) ❑ Unique patients tested increased (+56% vs P/Y) clonoSEQ test volume 8,998 7,698 6,850 17% 6,341 5,897 12% 5,300 8% 8%
Slide 5: Solidifying Adaptive's leadership in lymphoid cancers
Solidifying Adaptive's leadership in lymphoid cancers 400K patients Expand • Received Medicare coverage (DLBCL) into NHL • Preparing launch (DLBCL) Multiple Myeloma • MM in blood contributed 20% of MM Y/Y growth in blood • Expect MM data in blood by YE Driven by sales force expansion Market expansio
Slide 6: Data continues to emerge supporting MRD clinical utility
Data continues to emerge supporting MRD clinical utility MRD negative patients had best outcomes, irrespective of transplant DETERMINATION trial “The elimination of minimal residual disease is of increasing importance in tailoring treatment, in informing clinical care, and as a treatment goal given
Slide 7: MRD Business: pharma portfolio
MRD Business: pharma portfolio clonoSEQ use as an endpoint in heme clinical trials continues to grow Portfolio Overview Penetration Rate by Indication ◼ >60 BioPharma partners, 168 active clinical trials ◼ Overall penetration ~21%1 ◼ Partnership agreements include sequencing 189 336 101 80 revenue p
Slide 8: Immune Medicine Business Multi-line Strategy
Immune Medicine Business Platform synergies will drive growth opportunities and generate revenue Immune Medicine Platform Areas of Growth Multiple shots on goal to create value, grow and monetize our immune medicine platform across clinical applications T cells Pharma Services Pharma Services Multi-
Slide 9: Unlocking the value of T-cell immune receptor data at every step
Unlocking the value of T-cell immune receptor data at every step Pharma Services Drug Discovery Economics ($) RUO Regulated Use Therapeutics Target Discovery Validated diagnostic use Incorporated in FDA filing TCR/Antigen Map ✓T-MAP RSV TCR sequencing ✓T-MAP COVID ✓T-MAP RSV ✓Main TCR assay ✓Oncolog
Slide 10: Realigning T-Detect path to commercialization
Realigning T-Detect path to commercialization Clinical Testing Short/mid term monetization ✓ Platform validation through pharma Long-term positioning T-Detect COVID (EUA) Signal generation data Clinical testing: 1 blood test, • Offered to consumer • Improve confirmed signals multiple indications • C
Slide 11: Q2 2022 Key Financial Highlights
Q2 2022 Key Financial Highlights Total Revenue ($M) MRD Revenue ($M) + $43.7 +13% [Clinical testing $38.5 + pharma sequencing] 21.3 +38% 15.5 3 * Immune Medicine Revenue ($M) 23.0 22.4 -3% + Q2 2021 Q2 2022 MRD Business Immune Medicine Business All $ and % figures are rounded * 11 * Includes Academi
Slide 12: Q2 2022 Key Financial Highlights Cont.
Q2 2022 Key Financial Highlights Cont. Operating Expenses ($M) Strong Balance Sheet ◼ ~$450M in cash, cash equivalents and marketable +9% securities as of 06/30/2022 -6% ◼ Quarterly cash burn ~$55M in 2H 2022 $102 0.4 $96 FY 2022 Revenue Guidance $88 0.4 0.4 24 ◼ Reiterate FY range $185M-$195M 21 16
Slide 13: Updated Key Catalysts 2022
Updated Key Catalysts 2022 ◼ COVID T-cell response: focus on correlate of protection ◼ Scale T-MAP and drug discovery opportunities with pharma Immune ◼ Genentech collaboration: ✓ Selected TCR candidate to progress as a potential therapeutic product candidate Medicine ❑ Deliver 2 additional TCR data
Slide 14: Thank You.
Thank You.
Adaptive Biotechnologies — Q2 2022 Earnings Presentation on 6ix